3 Stocks Getting Rare Double Upgrades From Analysts

Several analysts have issued double upgrades for Advance Auto Parts (AAP), BioLineRx (BLRX), and Anheuser-Busch InBev (BUD) following their recent earnings reports. Redburn Partners upgraded AAP from Sell to Neutral based on its turnaround plan and potential for gross margin improvements, while Jones Trading upgraded BLRX to Strong Buy due to the commercialization of APHEXDA and focus on its oncology pipeline. BNP Paribas upgraded BUD to Strong Buy after a Q1 earnings report that beat EPS estimates despite revenue misses, citing the strength of its brands and growing non-alcoholic beer category, though some analysts believe other stocks may be better buys.

Analysis

Amidst a 2025 market characterized by uncertainty from tariffs, interest rates, and inflation, recent analyst double upgrades highlight potential opportunities. Advance Auto Parts (AAP), currently priced at $52.21, received an upgrade from Sell to Neutral by Redburn Partners, with a price target increase from $28 to $45, based on its multi-year turnaround plan showing progress beyond cost-cutting and toward potential gross margin improvements from supply chain efficiencies and private label brands; however, the average analyst 12-month forecast of $46.01 suggests an 11.88% downside. BioLineRx (BLRX), a biopharmaceutical firm, saw its stock upgraded from Hold to a Strong Buy by Jones Trading, with analysts forecasting a significant 362.63% upside to $26.00 from its current $5.62 price. This optimism follows the transfer of U.S. commercial rights for its multiple myeloma drug APHEXDA, approved in late 2023, allowing BLRX to focus on its oncology pipeline, notably motixafortid for pancreatic cancer, while de-risking from APHEXDA's commercialization cash burn via an equity stake and future milestone/royalty payments. Anheuser-Busch InBev (BUD), trading at $71.02, was upgraded by BNP Paribas from Hold to Strong Buy after its Q1 2025 earnings, where it beat EPS estimates by over 10% despite a slight revenue miss on falling volume. This performance, attributed to strong brands and a growing non-alcoholic beer segment, came despite sector pressures from inflation, higher interest rates, the GLP-1 movement, and a reported 49% of Americans planning to drink less in 2025; the average analyst price target of $71.50 indicates a marginal 0.68% upside.

Key Decisions for Investors

• Investors should scrutinize Advance Auto Parts' turnaround execution, as its current price of $52.21 significantly exceeds both Redburn Partners' $45 target and the average analyst forecast of $46.01, suggesting the recent upgrade to Neutral may already be priced in or that considerable further improvement is needed to justify current levels.
• BioLineRx presents a high-risk, high-reward scenario typical of development-stage biotech; the substantial forecasted upside to $26.00 warrants consideration for portfolios with appropriate risk tolerance, contingent on continued positive developments in its oncology pipeline, particularly for motixafortid, and successful monetization of APHEXDA through its partnership.
• For Anheuser-Busch InBev, the strong Q1 EPS performance and brand resilience offer defensive appeal, but the limited 0.68% upside to the average price target of $71.50 and significant headwinds from changing consumer alcohol consumption patterns and the GLP-1 trend warrant a cautious approach, potentially favoring it as a hold rather than a strong buy.
• Recognize that double analyst upgrades, while indicative of increased conviction and often a response to evolving company fundamentals, should prompt deeper due diligence into whether the market has already assimilated this positive sentiment, especially when current prices approach or exceed new targets.